Serum miR-222-3p as a Double-Edged Sword in Predicting Efficacy and Trastuzumab-Induced Cardiotoxicity for HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Target Therapy

Background: We aimed to explore whether the expression of serum miR-222-3p might contribute to early prediction of therapeutic response, clinical outcomes, and adverse events for HER2-positive breast cancer patients receiving neoadjuvant therapy (NAT). Methods: A total of 65 HER2-positive breast can...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Oncol
Autors principals: Zhang, Shan, Wang, Yaohui, Wang, Yan, Peng, Jing, Yuan, Chenwei, Zhou, Liheng, Xu, Shuguang, Lin, Yanping, Du, Yueyao, Yang, Fan, Zhang, Jie, Dai, Huijuan, Yin, Wenjin, Lu, Jinsong
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2020
Matèries:
Oncology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7212359/
https://ncbi.nlm.nih.gov/pubmed/32426280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.00631
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars